CRP and cardiovascular disorder: Therapies that decrease inflammation lower levels of non-specific inflammatory biomarkers such as c-reactive protein (CRP)7, reduce cardiovascular disease risk8 and improve cardiometabolic indices including levels of glucose and insulin which would subsequently lead to disease reduction9.